Sonoma Pharmaceuticals, Inc. (SNOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on January 29, 2025. The company, incorporated in Delaware and headquartered in Boulder, Colorado, operates in the pharmaceutical sector with a focus on Microcyn technology-based products. The report discloses a material definitive agreement entered into on the date of the report.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on the execution of a new commercial agreement rather than periodic financial performance.
Material Changes
The primary material change reported is the entry into a Master Supply Agreement with WellSpring Pharmaceutical Corporation, effective January 29, 2025. Key terms include:
- Counterparty: WellSpring Pharmaceutical Corporation.
- Product Scope: Sale of Microcyn technology-based products to large retailers in the United States.
- Term: Initial term of two years.
- Renewal: Subject to three automatic one-year renewal periods.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the company's intentions and expectations related to the new agreement. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. The company explicitly states it does not undertake an obligation to update these forward-looking statements except as required by law. Certain portions of the Master Supply Agreement were omitted from the filing to preserve confidentiality.
Investor Verification Checklist
- Verify the full text of the Master Supply Agreement (Exhibit 10.1) for specific pricing, volume commitments, and termination clauses, as portions were redacted in this filing.
- Review the company's most recent Form 10-K for detailed risk factors and historical financial performance.
- Confirm the operational capabilities of WellSpring Pharmaceutical Corporation to distribute to large U.S. retailers.
- Monitor future filings for updates on the execution of the agreement and any impact on quarterly revenue guidance.